Recombinant humanized monoclonal antibody antiIL-1β(Cp Guojian)
- Generic Name
- Recombinant humanized monoclonal antibody antiIL-1β(Cp Guojian)
The MAD Study of SSGJ-613 in Healthy Subjects
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Target Recruit Count
- 36
- Registration Number
- NCT05966701
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
Phase 1
- Conditions
- Periodic Fever SyndromeSystemic Juvenile Idiopathic Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2021-08-30
- Target Recruit Count
- 34
- Registration Number
- NCT05027373
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath